Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 2/20 | 0.42 |
| ▸ | MDM4 | O15151 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 2/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.41 |
| ▸ | SLC17A5 | Q9NRA2 | 1/20 | 0.41 |
| ▸ | TLR2 | O60603 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29400880 | 0.94 | MDM2 (0.44) | MDM2MDM4TP53PTPN1TLR2 | |
| SCHEMBL17322761 | 0.94 | MDM2 (0.44) | MDM2MDM4TP53PTPN1TLR2 | |
| SCHEMBL29400784 | 0.94 | MDM2 (0.44) | MDM2MDM4TP53PTPN1TLR2 | |
| SCHEMBL27728772 | 0.87 | MDM4 (0.49) | MDM2MDM4TP53TLR2 | |
| SCHEMBL14436881 | 0.86 | MDM2 (0.47) | MDM2MDM4TP53TLR2 | |
| SCHEMBL29401312 | 0.84 | CASP3 (0.44) | MDM2MDM4TP53 | |
| SCHEMBL29398411 | 0.84 | CASP3 (0.44) | MDM2MDM4TP53 | |
| SCHEMBL28152571 | 0.84 | MDM2 (0.46) | MDM2MDM4TP53PTPN1TLR2 | |
| SCHEMBL18576004 | 0.84 | MDM2 (0.46) | MDM2MDM4TP53TLR2 | |
| SCHEMBL117964 | 0.84 | MDM2 (0.55) | MDM2MDM4TP53SLC17A5TLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230265429-A1 | SKELETAL MUSCLE DELIVERY PLATFORMS AND METHODS OF USE THEREOF | Arrowhead Pharmaceuticals, Inc. | 2023-08-24 | — | — | US | disclosed |
| US-20230226193-A1 | LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS | Arrowhead Pharmaceuticals, Inc. | 2023-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230226193-A1 | LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS | CPT1B, MUSK, MYLK2 | MDM2 3966/4885MDM4 4317/4885TP53 4012/4885 |
| US-20230265429-A1 | SKELETAL MUSCLE DELIVERY PLATFORMS AND METHODS OF USE THEREOF | MUSK, MYLK2, TNNC1 | MDM2 3780/4885MDM4 4563/4885TP53 4218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.